Back
Compare AU
Compare RGOS vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Russell Sust Global Opportunities Complex ETF (RGOS) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
RGOS | CURE | |
|---|---|---|
Popularity | N/A | Low |
Pearlers invested | 0 | 66 |
Median incremental investment | $0 | $665.63 |
Median investment frequency | N/A | Monthly |
Median total investment | $0 | $1,934.40 |
Average age group | N/A | > 35 |
Key Summary
RGOS | CURE | |
|---|---|---|
Strategy | RGOS.AX was created on 2024-04-12 by Russell. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to outperform the Funds benchmark, before costs and tax, over the long term by providing exposure to a diversified portfolio of predominantly international shares. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 40.41m in AUM and 144 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | Microsoft Corp (4.10 %) NVIDIA Corp (2.96 %) Apple Inc (2.51 %) | Moderna Inc (2.14 %) Roivant Sciences Ltd Ordinary Shares (1.69 %) Vaxcyte Inc Ordinary Shares (1.66 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | |
Top 3 countries | United States (62.52 %) United Kingdom of Great Britain and Northern Ireland (5.93 %) France (5.27 %) | United States (96.62 %) United Kingdom of Great Britain and Northern Ireland (1.35 %) Switzerland (1.13 %) |
Management fee | 0 % | 0.45 % |
Key Summary
RGOS | CURE | |
|---|---|---|
Issuer | Russell | Global X |
Tracking index | S&P Biotechnology Select Industry | |
Asset class | ETF | ETF |
Management fee | 0 % | 0.45 % |
Price | $21.62 | $60.45 |
Size | N/A | $40.284 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 4.97 % | 5.08 % |
Market | ASX | ASX |
First listed date | 15/04/2024 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
RGOS | CURE | |
|---|---|---|
Popularity | N/A | Low |
Pearlers invested | 0 | 66 |
Median incremental investment | $0 | $665.63 |
Median investment frequency | N/A | Monthly |
Median total investment | $0 | $1,934.40 |
Average age group | N/A | > 35 |
Pros and Cons
RGOS | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
RGOS | CURE |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |